Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • Three major brokerages assign BUY ratings to Kooth, with upside potential as high as 231%.

  • California rollout of Soluna reaches over 128,000 users, with strong state-level support.

  • £15.1M cash balance and strategic leadership transition underpin future expansion plans.

Kooth Plc (LSE:KOO), a pioneering provider of digital mental health solutions, has received a wave of optimism from the market as three leading analysts – Stifel Europe, Canaccord Genuity, and Berenberg – reaffirmed BUY ratings

Based on their updated price targets, Kooth’s stock could witness a potential upside ranging from 91% to over 230%.

Analysts Predict Aggressive Upside Potential

Analyst sentiment around Kooth has turned sharply positive, likely due to its continued progress in California and current financial standing. The company has received the following ratings:

  • Stifel Europe maintained a BUY rating, projecting a target price of 10.65 GBP, implying a 231% upside from the current price level.

  • Canaccord Genuity echoed similar confidence with a BUY recommendation, assigning a target price of 10.04 GBP, which translates into a 212% upside.

  • Berenberg has also reiterated its BUY rating, with a price target of 6.15 GBP, representing an expected 91% share price increase.

U.S. Growth Trajectory Backed by California Success

Kooth continues to make substantial headway in its landmark digital mental health contract with the State of California, which has quickly emerged as a core revenue driver. The company’s Soluna platform, launched in January 2024, has already enrolled over 128,000 young users, with engagement metrics particularly positive in underserved communities.

The California Department of Health Care Services (DHCS) has recognised Soluna as an innovative tool in reshaping behavioural health delivery. 

Financial Resilience and Leadership Execution in Focus

Kooth reported £15.1 million in unaudited net cash as of June 2025, following focused investments in marketing, user acquisition, and product rollout across the U.S. These investments might be seen by analysts as necessary groundwork for long-term growth.

At the executive level, Kate Newhouse has formally assumed the role of CEO, succeeding Tim Barker. Her emphasis on expanding U.S. operations through targeted senior hires and international alignment is viewed as a critical enabler for Kooth’s next phase of growth.

While NHS reorganisation and fiscal tightening continue to challenge UK public health spending, Kooth has maintained stable operations domestically.